Overview

Study of Efficacy and Safety of MAS825 in Patients With COVID-19

Status:
Completed
Trial end date:
2021-04-21
Target enrollment:
Participant gender:
Summary
The study will assess the efficacy and safety of MAS825 for the treatment of SARS-CoV-2 infected patients with COVID-19 pneumonia and impaired respiratory function
Phase:
Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals